Developer docs
API playgroundTry for free, no card

Search company profiles

Trevena

Full company profile

uuid0003r86

Namestring
Trevena
Legal namestring
Trevena, Inc.
Websiteurl
trevena.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Trevena, Inc. (NASDAQ/Pink Sheets: TRVN) is a biopharmaceutical company founded in 2007 (originally as Parallax Therapeutics, Inc.) and headquartered in Atlanta, GA. It operates as a clinical-stage CNS-focused drug developer built on the proprietary ABLE (Advanced Biased Ligand Explorer) platform, which screens for G protein-coupled receptor (GPCR) biased ligands that selectively activate one signaling pathway (G protein or beta-arrestin) while inhibiting the other. The scientific foundation traces to Nobel laureate Dr. Robert Lefkowitz's GPCR research.

The company's commercial portfolio consists of one FDA-approved product, OLINVYK (oliceridine) injection — an IV mu-receptor biased ligand indicated for acute pain in adults — plus three Phase 1 investigational candidates: TRV045 (S1P receptor, diabetic neuropathic pain and epilepsy), TRV250 (delta receptor, acute migraine), and TRV734 (mu receptor, opioid use disorder). The TRV027 acute-heart-failure program is subject to an exclusive license option held by Forest Laboratories. Trevena has a 51-100 employee organization and reaches acute care hospitals via field sales and medical-affairs channels; its geographic footprint spans the United States and, through Jiangsu Nhwa, China.

Trevena's revenue model combines direct OLINVYK product sales (one-time licensing/transaction structure for institutional acute care), milestone payments and tiered royalties tied to OLINVYK commercial milestones, a non-dilutive royalty-based financing arrangement with R-Bridge Healthcare Fund (CBC Group) covering up to $40 million across US and China rights, and a contingent Forest option on TRV027 that could yield up to $65 million upfront plus $430 million in milestones. Disclosed 2023 revenue was $3.125 million; the company has experienced large operating losses, a reverse stock split in August 2024, and a Nasdaq delisting notification in October 2024, with the stock now trading on Pink Sheets.

Short descriptiontext

Trevena is a CNS-focused biopharmaceutical company commercializing the FDA-approved acute-pain drug OLINVYK (oliceridine) and developing three Phase 1 biased-ligand candidates (TRV045, TRV250, TRV734) for CNS disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKing Of Prussia, United States
HQ citystring
King Of Prussia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biased ligand therapeutics, CNS drug development, opioid analgesics, GPCR drug discovery, acute pain management
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Biopharmaceuticals (CNS Therapeutics)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - OLINVYK
TypeOne Time License
Description

Revenue from commercial sales of OLINVYK (oliceridine) injection in the US market for acute pain management.

reuters.com
2Royalty Financing - R-Bridge Healthcare Fund
TypeLicensing Royalties
Description

Non-dilutive royalty-based financing providing upfront payments and additional payments based on sales milestones and approvals for OLINVYK in China and US markets.

trevena.com
3Milestone Payments
TypeLicensing Royalties
Description

Potential milestone payments of up to $8 million based on US partnership milestones for OLINVYK commercialization.

trevena.com
4Forest Laboratories Option
TypeLicensing Royalties
Description

Potential upfront option exercise fee of $65 million and milestone payments up to $430 million total, plus tiered royalties of 10-20% on net sales if Forest exercises option for TRV027.

trevena.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1OLINVYK (oliceridine) injection
Description

FDA-approved product for acute pain management, a mu receptor agonist.

trevena.com
Core offering1 text field

Trevena is a biopharmaceutical company that discovers, develops and commercializes GPCR-targeted biased ligands for central nervous system (CNS) disorders. Its commercial offering is OLINVYK (oliceridine) injection, an FDA-approved intravenous analgesic for acute pain in adults, while its development pipeline comprises TRV045 (S1P receptor), TRV250 (delta receptor) and TRV734 (mu receptor)—all Phase 1 candidates. The company leverages its proprietary Advanced Biased Ligand Explorer (ABLE) drug discovery platform to identify biased ligands with potentially improved therapeutic profiles over conventional drugs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • TRV130 showed superior analgesia compared to high dose morphine with less respiratory depression, nausea and vomiting in Phase 1b trial
+1 more record
Product overview1 text field

Trevena is a biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company's product portfolio consists of one FDA-approved product—OLINVYK (oliceridine) injection, an intravenous analgesic for acute pain—and three differentiated investigational drug candidates in various phases of clinical development: TRV045 (S1P receptor for diabetic neuropathic pain and epilepsy), TRV250 (delta receptor for acute migraine), and TRV734 (mu receptor for opioid use disorder). The pipeline is built on the company's ABLE (Advanced Biased Ligand Explorer) platform, which enables the discovery of biased ligands that selectively activate specific G-protein coupled receptor signaling pathways to potentially improve therapeutic profiles.

Product and service5 records
1OLINVYK (oliceridine) injection
CategoryFDA-approved pharmaceutical product (CNS / acute pain)
Description

OLINVYK is an FDA-approved intravenous mu receptor agonist analgesic for the management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate. It was developed using Trevena's biased ligand approach targeting G-protein signaling while minimizing beta-arrestin pathways, marketed to U.S. acute care hospitals and healthcare providers.

2TRV045
CategoryInvestigational drug candidate (Phase 1, CNS)
Description

TRV045 is an S1P receptor-targeting biased ligand compound in Phase 1 clinical trials being developed for the treatment of diabetic neuropathic pain and epilepsy. It is administered orally.

3TRV250
CategoryInvestigational drug candidate (Phase 1, CNS)
Description

TRV250 is a delta receptor-targeting compound in Phase 1 clinical development for the acute treatment of migraine. It is administered orally or subcutaneously.

4TRV734
CategoryInvestigational drug candidate (Phase 1, CNS)
Description

TRV734 is a mu receptor-targeting oral biased ligand in Phase 1 clinical trials for maintenance treatment of opioid use disorder, leveraging Trevena's biased ligand technology platform.

5TRV027
CategoryInvestigational drug candidate (optioned to Forest Laboratories)
Description

TRV027 is a beta-arrestin biased ligand targeting the AT1R receptor for acute heart failure, currently subject to an exclusive option held by Forest Laboratories Holdings. If exercised, Trevena could receive up to $430 million in milestones plus tiered 10–20% royalties on net sales.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-09-06
Description

Chinese licensee that made first commercial sale of OLINVYK in China, triggering $15 million milestone payment to Trevena. Jiangsu Nhwa is responsible for commercialization of OLINVYK in the Chinese market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-05-03
Description

Forest has exclusive option to license TRV027 for acute heart failure. If Forest exercises option, they receive worldwide development and commercialization rights and Trevena could receive up to $430 million in milestones plus 10-20% royalties on net sales.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical company focused on acute pain management with FDA-approved product Dsuvia (sufentanil sublingual). Most directly comparable to Trevena given similar size, single-product focus on hospital-administered analgesics, and recent commercial challenges.

TypeDirect peer
Description

Specialty pharmaceutical company commercializing pain products including Xtampza ER and the recently acquired Belbuca. Direct peer in pain specialty pharma with established commercial infrastructure in the same hospital/prescriber channels as OLINVYK.

TypeDirect peer
Description

Specialty pharmaceutical company with FDA-approved pain and supportive care products (Cinvanti, Zynrelef). Similar size, specialty focus, and product portfolio depth to Trevena's OLINVYK-driven business.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel pain therapeutics including Korsuva (difelikefalin). Highly comparable as a small-cap CNS/pain biopharma with differentiated mechanism and pipeline of pain indications.

TypeDirect peer
Description

Clinical-stage CNS specialty pharmaceutical company developing treatments for migraine, fibromyalgia, and other CNS disorders. Comparable size, similar CNS focus, and similar early-stage pipeline profile to Trevena.

TypeBroad incumbent
Description

Established CNS specialty pharmaceutical company with commercial products (Nuplazid, Daybue). Comparable therapeutic focus on CNS disorders but with significantly greater scale, multiple approved products, and broader commercial reach than Trevena.

TypeBroad incumbent
Description

CNS-focused specialty pharmaceutical company with multiple approved products in neurology (Trokendi XR, Oxtellar XR, Qelbree). Operates in similar CNS therapeutic categories but with established commercial portfolio and broader pipeline.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company using AI-driven drug discovery for CNS and immuno-oncology indications. Similar small-cap, CNS-focused profile with early-stage pipeline assets.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing precision medicines for neuroscience diseases. Comparable CNS therapeutic focus with similar small-cap, pipeline-driven profile to Trevena.

TypeBroad incumbent
Description

Large-cap biopharmaceutical company that recently received FDA approval for Journavx (suzetrigine), a novel non-opioid acute pain therapeutic. Competes directly with OLINVYK in the acute pain space with significantly greater resources and commercial scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trevena

Specialty Biopharmaceuticals (CNS Therapeutics)trevena.com

Trevena is a CNS-focused biopharmaceutical company commercializing the FDA-approved acute-pain drug OLINVYK (oliceridine) and developing three Phase 1 biased-ligand candidates (TRV045, TRV250, TRV734) for CNS disorders.

What Trevena does

Trevena, Inc. (NASDAQ/Pink Sheets: TRVN) is a biopharmaceutical company founded in 2007 (originally as Parallax Therapeutics, Inc.) and headquartered in Atlanta, GA. It operates as a clinical-stage CNS-focused drug developer built on the proprietary ABLE (Advanced Biased Ligand Explorer) platform, which screens for G protein-coupled receptor (GPCR) biased ligands that selectively activate one signaling pathway (G protein or beta-arrestin) while inhibiting the other. The scientific foundation traces to Nobel laureate Dr. Robert Lefkowitz's GPCR research.

The company's commercial portfolio consists of one FDA-approved product, OLINVYK (oliceridine) injection — an IV mu-receptor biased ligand indicated for acute pain in adults — plus three Phase 1 investigational candidates: TRV045 (S1P receptor, diabetic neuropathic pain and epilepsy), TRV250 (delta receptor, acute migraine), and TRV734 (mu receptor, opioid use disorder). The TRV027 acute-heart-failure program is subject to an exclusive license option held by Forest Laboratories. Trevena has a 51-100 employee organization and reaches acute care hospitals via field sales and medical-affairs channels; its geographic footprint spans the United States and, through Jiangsu Nhwa, China.

Trevena's revenue model combines direct OLINVYK product sales (one-time licensing/transaction structure for institutional acute care), milestone payments and tiered royalties tied to OLINVYK commercial milestones, a non-dilutive royalty-based financing arrangement with R-Bridge Healthcare Fund (CBC Group) covering up to $40 million across US and China rights, and a contingent Forest option on TRV027 that could yield up to $65 million upfront plus $430 million in milestones. Disclosed 2023 revenue was $3.125 million; the company has experienced large operating losses, a reverse stock split in August 2024, and a Nasdaq delisting notification in October 2024, with the stock now trading on Pink Sheets.

Trevena firmographics

Firmographics
Name
Trevena
Legal name
Trevena, Inc.
Website
https://trevena.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Trevena is a CNS-focused biopharmaceutical company commercializing the FDA-approved acute-pain drug OLINVYK (oliceridine) and developing three Phase 1 biased-ligand candidates (TRV045, TRV250, TRV734) for CNS disorders.
Ownership category
akta.pro rank

Trevena industry classification

Industry
Product category
Specialty Biopharmaceuticals (CNS Therapeutics)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Biased ligand therapeutics
  • CNS drug development
  • Opioid analgesics
  • GPCR drug discovery
  • Acute pain management

Where Trevena is headquartered

Location

Headquarters

HQ city
King Of Prussia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Trevena business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - OLINVYK: Revenue from commercial sales of OLINVYK (oliceridine) injection in the US market for acute pain management.
  2. Royalty Financing - R-Bridge Healthcare Fund: Non-dilutive royalty-based financing providing upfront payments and additional payments based on sales milestones and approvals for OLINVYK in China and US markets.
  3. Milestone Payments: Potential milestone payments of up to $8 million based on US partnership milestones for OLINVYK commercialization.
  4. Forest Laboratories Option: Potential upfront option exercise fee of $65 million and milestone payments up to $430 million total, plus tiered royalties of 10-20% on net sales if Forest exercises option for TRV027.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Trevena product offering

Product offering

Core offering

Trevena is a biopharmaceutical company that discovers, develops and commercializes GPCR-targeted biased ligands for central nervous system (CNS) disorders. Its commercial offering is OLINVYK (oliceridine) injection, an FDA-approved intravenous analgesic for acute pain in adults, while its development pipeline comprises TRV045 (S1P receptor), TRV250 (delta receptor) and TRV734 (mu receptor)—all Phase 1 candidates. The company leverages its proprietary Advanced Biased Ligand Explorer (ABLE) drug discovery platform to identify biased ligands with potentially improved therapeutic profiles over conventional drugs.

Product overview

Trevena is a biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company's product portfolio consists of one FDA-approved product—OLINVYK (oliceridine) injection, an intravenous analgesic for acute pain—and three differentiated investigational drug candidates in various phases of clinical development: TRV045 (S1P receptor for diabetic neuropathic pain and epilepsy), TRV250 (delta receptor for acute migraine), and TRV734 (mu receptor for opioid use disorder). The pipeline is built on the company's ABLE (Advanced Biased Ligand Explorer) platform, which enables the discovery of biased ligands that selectively activate specific G-protein coupled receptor signaling pathways to potentially improve therapeutic profiles.

Differentiator

Problem solved

Functional benefit

Brands

  • OLINVYK (oliceridine) injection: FDA-approved product for acute pain management, a mu receptor agonist.

Products and services

  • OLINVYK (oliceridine) injection OLINVYK is an FDA-approved intravenous mu receptor agonist analgesic for the management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate. It was developed using Trevena's biased ligand approach targeting G-protein signaling while minimizing beta-arrestin pathways, marketed to U.S. acute care hospitals and healthcare providers.
  • TRV045 TRV045 is an S1P receptor-targeting biased ligand compound in Phase 1 clinical trials being developed for the treatment of diabetic neuropathic pain and epilepsy. It is administered orally.
  • TRV250 TRV250 is a delta receptor-targeting compound in Phase 1 clinical development for the acute treatment of migraine. It is administered orally or subcutaneously.
  • TRV734 TRV734 is a mu receptor-targeting oral biased ligand in Phase 1 clinical trials for maintenance treatment of opioid use disorder, leveraging Trevena's biased ligand technology platform.
  • TRV027 TRV027 is a beta-arrestin biased ligand targeting the AT1R receptor for acute heart failure, currently subject to an exclusive option held by Forest Laboratories Holdings. If exercised, Trevena could receive up to $430 million in milestones plus tiered 10–20% royalties on net sales.

Quantifiable outcome

  • TRV130 showed superior analgesia compared to high dose morphine with less respiratory depression, nausea and vomiting in Phase 1b trial
  • +1 more outcomes

Companies that use Trevena

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Trevena technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Trevena partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Jiangsu NhwacoreChannel Partner/ Reseller/ Distributor · 6 September 2023Chinese licensee that made first commercial sale of OLINVYK in China, triggering $15 million milestone payment to Trevena. Jiangsu Nhwa is responsible for commercialization of OLINVYK in the Chinese market.
  • Forest Laboratories Holdings LimitedcoreStrategic or Co-development Partner · 3 May 2013Forest has exclusive option to license TRV027 for acute heart failure. If Forest exercises option, they receive worldwide development and commercialization rights and Trevena could receive up to $430 million in milestones plus 10-20% royalties on net sales.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Trevena competitors and assessment

Company assessment

Direct peers

  • AcelRx Pharmaceuticals: Specialty pharmaceutical company focused on acute pain management with FDA-approved product Dsuvia (sufentanil sublingual). Most directly comparable to Trevena given similar size, single-product focus on hospital-administered analgesics, and recent commercial challenges.
  • Collegium Pharmaceutical: Specialty pharmaceutical company commercializing pain products including Xtampza ER and the recently acquired Belbuca. Direct peer in pain specialty pharma with established commercial infrastructure in the same hospital/prescriber channels as OLINVYK.
  • Heron Therapeutics: Specialty pharmaceutical company with FDA-approved pain and supportive care products (Cinvanti, Zynrelef). Similar size, specialty focus, and product portfolio depth to Trevena's OLINVYK-driven business.
  • Cara Therapeutics: Clinical-stage biopharmaceutical company developing novel pain therapeutics including Korsuva (difelikefalin). Highly comparable as a small-cap CNS/pain biopharma with differentiated mechanism and pipeline of pain indications.
  • Tonix Pharmaceuticals: Clinical-stage CNS specialty pharmaceutical company developing treatments for migraine, fibromyalgia, and other CNS disorders. Comparable size, similar CNS focus, and similar early-stage pipeline profile to Trevena.

Broad incumbents

  • Acadia Pharmaceuticals: Established CNS specialty pharmaceutical company with commercial products (Nuplazid, Daybue). Comparable therapeutic focus on CNS disorders but with significantly greater scale, multiple approved products, and broader commercial reach than Trevena.
  • Supernus Pharmaceuticals: CNS-focused specialty pharmaceutical company with multiple approved products in neurology (Trokendi XR, Oxtellar XR, Qelbree). Operates in similar CNS therapeutic categories but with established commercial portfolio and broader pipeline.
  • Vertex Pharmaceuticals: Large-cap biopharmaceutical company that recently received FDA approval for Journavx (suzetrigine), a novel non-opioid acute pain therapeutic. Competes directly with OLINVYK in the acute pain space with significantly greater resources and commercial scale.

Emerging players

  • BioXcel Therapeutics: Clinical-stage biopharmaceutical company using AI-driven drug discovery for CNS and immuno-oncology indications. Similar small-cap, CNS-focused profile with early-stage pipeline assets.
  • Neumora Therapeutics: Clinical-stage biopharmaceutical company developing precision medicines for neuroscience diseases. Comparable CNS therapeutic focus with similar small-cap, pipeline-driven profile to Trevena.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Trevena social profiles

Digital presence

Trevena financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trevena leadership team

Management profile

Number of profiles

Profiles10 records

Trevena funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trevena M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trevena

What does Trevena do?

Trevena is a biopharmaceutical company that discovers, develops and commercializes GPCR-targeted biased ligands for central nervous system (CNS) disorders. Its commercial offering is OLINVYK (oliceridine) injection, an FDA-approved intravenous analgesic for acute pain in adults, while its development pipeline comprises TRV045 (S1P receptor), TRV250 (delta receptor) and TRV734 (mu receptor)—all Phase 1 candidates. The company leverages its proprietary Advanced Biased Ligand Explorer (ABLE) drug discovery platform to identify biased ligands with potentially improved therapeutic profiles over conventional drugs.

Is Trevena a public or private company?

Trevena is a public company. It is classified as public and is currently operating.

When was Trevena founded?

Trevena was founded in 2007. It employs 11 to 50 people.

Where is Trevena based?

Trevena is headquartered in King Of Prussia, United States, in the North America region.

How does Trevena make money?

Four revenue lines are on record. Product Sales - OLINVYK is the primary driver. The others are royalty Financing - R-Bridge Healthcare Fund, milestone Payments and forest Laboratories Option.

Who are Trevena's main competitors?

Direct peers on record are AcelRx Pharmaceuticals, Collegium Pharmaceutical, Heron Therapeutics, Cara Therapeutics and Tonix Pharmaceuticals. Broad incumbents are Acadia Pharmaceuticals, Supernus Pharmaceuticals and Vertex Pharmaceuticals. Emerging players are BioXcel Therapeutics and Neumora Therapeutics.

Does Trevena have an API?

No public API is recorded for Trevena.

What industry is Trevena in?

Trevena's product category is Specialty Biopharmaceuticals (CNS Therapeutics). Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldTrevena (NASDAQ:TRVN) Share Price Crosses Above 50-Day Moving Average – Here’s What HappenedTrevena, Inc. (NASDAQ:TRVN) stock price passed above its 50-day moving average during trading on Thursday, reaching $0.0111 with a volume of 594 shares.Defense WorldTrevena (NASDAQ:TRVN) Share Price Crosses Above 50-Day Moving Average – Here’s What HappenedTrevena, Inc. (NASDAQ:TRVN) shares passed above the stock's 50-day moving average during trading on Wednesday, trading as high as $0.02 with a volume of 2,369 shares. The company has a market capitalization of $19,180, a PE ratio of 0.00, and a beta of 0.59, with a 200-day moving average of $0.03. Trevena is a clinical-stage biopharmaceutical company developing biased ligand GPCR-selective medicines, with its lead compound oliceridine (OLINVEO) designed for the treatment of moderate to severe acute pain in hospital settings.ReutersStock Price & Latest NewsTrevena Inc., a biopharmaceutical company in the US, has developed OLINVYK and has three investigational drug candidates targeting CNS disorders and pain management. The company reported a net income loss and a revenue of $3.125 million in 2023.BenzingaWhy Trevena (TRVN) Stock Is Down 43% Today - TREVENA INC by Trevena, Inc. (OTC:TRVN)Trevena Inc shares plummeted 43.3% after the company announced it would be delisted from the Nasdaq Stock Market effective October 8 due to failure to meet minimum stockholder equity requirements. Following this regulatory action, Trevena's stock is expected to move to the Pink Open Market, though broker facilitation is not guaranteed.GlobeNewswireTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty FinancingTrevena, Inc. has amended its ex-US royalty financing agreement with R-Bridge Healthcare Fund, securing an immediate $2 million tranche and potential future payments of up to $8 million contingent on US commercial milestones for OLINVYK. The amendment also reduces Trevena's outstanding liabilities by $10 million and adjusts terms regarding intellectual property pledges and warrant exercise prices.BioSpaceTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty FinancingTrevena, Inc. announced an amendment to its ex-US royalty financing agreement with R-Bridge Healthcare Fund, securing a $2 million immediate payment and eligibility for up to $8 million more based on commercial milestones for its drug OLINVYK. The amendment also reduces Trevena's outstanding liabilities by $10 million and modifies the terms of warrants issued to R-Bridge.AktienTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty FinancingTrevena, Inc. has amended its ex-US royalty financing agreement with R-Bridge Healthcare Fund to receive an immediate $2 million tranche and potentially up to $8 million more based on US commercialization milestones for its drug OLINVYK. The amendment also reduces Trevena's outstanding liabilities by $10 million and transfers certain Chinese intellectual property rights to the fund.YahooTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty FinancingTrevena, Inc. announced an amendment to its royalty financing agreement with R-Bridge Healthcare Fund, securing a $2 million payment and eligibility for up to $8 million more based on commercial milestones for its drug OLINVYK. The deal also reduces Trevena's outstanding liabilities by $10 million and transfers certain Chinese intellectual property rights to the lender.TrevenaTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty FinancingTrevena, Inc. announced an amendment to its existing ex-US royalty financing agreement with R-Bridge Healthcare Fund, securing a $2 million non-dilutive tranche and potential future payments of up to $8 million based on commercial milestones for its drug OLINVYK. The agreement also results in a $10 million reduction in Trevena's outstanding liabilities and involves the transfer of certain Chinese intellectual property rights to R-Bridge.TrevenaTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise :: Trevena, Inc. (TRVN)Trevena, Inc. closed a $4 million financing transaction comprising a $1.946 million private placement and the exercise of existing warrants at a reduced price of $0.70 per share. The company intends to use these net proceeds for general corporate and working capital purposes. Trevena believes this funding may satisfy conditions required to receive a $10.0 million tranche from its loan agreement with R-Bridge Healthcare Investment Advisory, Ltd.